Literature DB >> 14716057

Long-term survival after radical resection of advanced pancreatic cancer: a case report with special reference to CD8+ T-cell infiltration.

Motoki Abe1, Satoshi Kondo, Satoshi Hirano, Yoshiyasu Ambo, Eiichi Tanaka, Toshiaki Morikawa, Shunichi Okushiba, Hiroyuki Katoh.   

Abstract

A 65-yr-old man who underwent pancreaticoduodenectomy with portal vein resection for pancreatic cancer is alive 8 yr after surgery. Originally, computed tomography (CT) revealed an 8-cm tumor in the pancreatic head. The tumor had infiltrated the portal vein, but grew expansively, so there was neither biliary obstruction nor jaundice. Pancreaticoduodenectomy with resection of the portal vein was performed for pancreatic cancer. Many tumor-infiltrating lymphocytes were seen within cancer cell nests on routine histopathology. We performed immunostaining for CD8, and found that a large number of the lymphocytes were CD8+ T cells. The patient's prognosis was considered poor because the tumor was large and had infiltrated the portal vein. We suspect that long-term survival may be related to the response of CD8+ T cells to the cancer.

Entities:  

Mesh:

Year:  2003        PMID: 14716057     DOI: 10.1385/IJGC:33:2-3:107

Source DB:  PubMed          Journal:  Int J Gastrointest Cancer        ISSN: 1537-3649


  8 in total

1.  A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma.

Authors:  A K Eerola; Y Soini; P Pääkkö
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

2.  Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas.

Authors:  K Schumacher; W Haensch; C Röefzaad; P M Schlag
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

3.  Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity.

Authors:  O Nakano; M Sato; Y Naito; K Suzuki; S Orikasa; M Aizawa; Y Suzuki; I Shintaku; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

4.  Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators.

Authors:  T A Sohn; C J Yeo; J L Cameron; L Koniaris; S Kaushal; R A Abrams; P K Sauter; J Coleman; R H Hruban; K D Lillemoe
Journal:  J Gastrointest Surg       Date:  2000 Nov-Dec       Impact factor: 3.452

5.  Surgical possibilities for pancreatic cancer: extended resection.

Authors:  B Kremer; I Vogel; J Lüttges; G Klöppel; D Henne-Bruns
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

6.  Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas.

Authors:  G Benassai; M Mastrorilli; G Quarto; A Cappiello; U Giani; P Forestieri; F Mazzeo
Journal:  J Surg Oncol       Date:  2000-04       Impact factor: 3.454

7.  Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection.

Authors:  R Delcore; F J Rodriguez; J Forster; A S Hermreck; J H Thomas
Journal:  Am J Surg       Date:  1996-11       Impact factor: 2.565

8.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

Authors:  Y Naito; K Saito; K Shiiba; A Ohuchi; K Saigenji; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

  8 in total
  2 in total

1.  Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma.

Authors:  E J Clark; S Connor; M A Taylor; K K Madhavan; O J Garden; R W Parks
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

2.  Prognostic impact of the tumor-infiltrating regulatory T-cell (Foxp3+)/activated cytotoxic T lymphocyte (granzyme B+) ratio on resected left-sided pancreatic cancer.

Authors:  Ho Kyoung Hwang; Hyoung-Il Kim; Se Hoon Kim; Junjeong Choi; Chang Moo Kang; Kyung Sik Kim; Woo Jung Lee
Journal:  Oncol Lett       Date:  2016-10-13       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.